NovoCure NVCR Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $655.35M+8.3% | $605.22M+18.8% | $509.34M-5.3% | $537.84M+0.5% | ||
| $166.88M+21.6% | $137.18M+6.9% | $128.28M+11.7% | $114.87M0.0% | ||
| $488.47M+4.4% | $468.04M+22.8% | $381.06M-9.9% | $422.97M+0.7% | ||
| 74.5%-2.8pp | 77.3%+2.5pp | 74.8%-3.8pp | 78.6%+0.1pp | ||
| $224.54M+7.1% | $209.65M-6.0% | $223.06M+8.2% | $206.09M+2.4% | ||
| $240.06M+0.4% | $239.06M+5.4% | $226.81M+30.6% | $173.66M+26.7% | ||
| $177.67M-6.4% | $189.83M+15.7% | $164.06M+23.6% | $132.75M+5.3% | ||
| $642.27M+0.6% | $638.54M+4.0% | $613.93M+19.8% | $512.5M+10.3% | ||
| -$153.8M+9.8% | -$170.5M+26.8% | -$232.87M-160% | -$89.52M-102% | ||
| -23.5%+4.7pp | -28.2%+17.5pp | -45.7%-29.1pp | -16.6%-8.4pp | ||
| $18.11M-54.0% | $39.33M-4.4% | $41.13M+164% | $15.55M+2,828% | ||
| -$136.25M-3.9% | -$131.16M+31.6% | -$191.74M-134% | -$81.85M-57.2% | ||
| -$23K-100% | $37.47M+145% | $15.3M+43.2% | $10.69M+70.3% | ||
| -$136.23M+19.2% | -$168.63M+18.6% | -$207.04M-124% | -$92.53M-58.6% | ||
| -20.8%+7.1pp | -27.9%+12.8pp | -40.6%-23.4pp | -17.2%-6.3pp | ||
| -$1.22+21.8% | -$1.56+19.6% | -$1.94-120% | -$0.88-57.1% | ||
| -$139.15M+12.6% | -$159.26M+28.2% | -$221.9M-181% | -$78.9M-132% | ||
| -21.2%+5.1pp | -26.3%+17.3pp | -43.6%-28.9pp | -14.7%-8.3pp | ||
| -$153.8M+9.8% | -$170.5M+26.8% | -$232.87M-160% | -$89.52M-102% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NovoCure's profit margins?
- Gross margin is 75.2% and operating margin is -27.2%, with a -25.7% net margin.
- Where does NovoCure's income statement data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.